Johns Hopkins University Center for Bioengineering and Innovation Design

Cord blood, collected from the umbilical cord and placenta after live birth, is the most viable source of stem cells, yet over 99 percent is uncollected and discarded. One of the main reasons valuable cord blood is so frequently discarded is because no adequate collection method exists. TheraCord will solve the collection problem by developing an easy-to-use device, the CBx System, which is currently in the alpha prototype stage and undergoing bench testing at Johns Hopkins Hospital. The CBx System will allow any hospital to consistently provide cord blood banks with high quality cord blood units. TheraCord will expand the availability of stem cells, enabling and sustaining the growth of revolutionary regenerative therapies that could help treat over 300 million people worldwide. TheraCord's ultimate goal is to become the standard of care for cord blood collection for every hospital and every birth worldwide.